HLA-G and neoplasm: Therefore, targeting HLA-G/LILRB pathways with antibodies, alone or in combination with other ICIs, might constitute a promising strategy for breaking down tolerance in tumors and promoting rejuvenation of exhausted tumor-infiltrating immune cells.